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Abstract
Background: Clinically distinct autoimmune phenotypes share genetic susceptibility factors. We investigated the
prevalence of familial autoimmunity among subjects with juvenile idiopathic arthritis (JIA), childhood systemic lupus
erythematosus (cSLE) and juvenile dermatomyositis (JDM) in the CARRA Registry, the largest multicenter observational
Registry for pediatric rheumatic disease.
Methods: Children with JIA, cSLE and JDM enrolled in the CARRA Registry between May 2010 and May 2012 were
investigated for differences in proportion of subjects who had first-degree relatives (FDR) with autoimmunity. If a
significant difference was detected, pairwise comparisons, adjusted for multiple comparisons, were made.
Results: There were 4677 JIA, 639 cSLE and 440 JDM subjects. The proportion of subjects having FDR with any
autoimmune disease in the JDM group (20.5 %) was less compared to subjects with JIA (31.8 %, p < 0.001) or SLE
(31.9 %; p < 0.001). Significantly greater proportion of JIA cases had FDR with inflammatory arthritis (13 %) compared to
cSLE (9.2 %, p = 0.007) or JDM (4.3 %, p <0.001). Significantly greater proportion of cSLE cases had FDR with SLE (11.1 %
vs. 1.7 % for JIA and 1.1 % for JDM p < 0.001) or type-I diabetes (7.4 % for cSLE vs. 3.1 % for JIA and 3.0 % for JDM
p < 0.001).
Conclusion: Higher proportions of subjects with JIA and cSLE have FDR with autoimmunity compared to those of
JDM. Relatives of cSLE cases had an increased prevalence of SLE, and relatives of JIA cases were enriched for
inflammatory arthropathies demonstrating distinct patterns of familial autoimmunity among these phenotypes.
Background
Autoimmune disorders are relatively common, estimated
to affect 5 to 10 % of the population. Juvenile idiopathic
arthritis (JIA), childhood onset systemic lupus erythema-
tosus (cSLE) and juvenile dermatomyositis (JDM) are ex-
amples of autoimmune disorders affecting the pediatric
population. Although autoimmune disorders are clinic-
ally distinct phenotypes, there is substantial evidence to
suggest that they may share common genetic susceptibility
factors. Variants in PTPN22 and STAT4 genes exemplify
genetic variants associated with multiple autoimmune
phenotypes [1–4].
There is also clinical evidence for the clustering of
autoimmunity in individuals and families [5, 6]. For in-
stance, children with JIA have increased prevalence of
autoimmune thyroiditis and type 1 diabetes [7, 8]. Rela-
tives of children with JIA,, cSLE and JDM have a higher
prevalence of autoimmunity [9–11]. In some instances,
two autoimmune phenotypes show inverse relationships.
While RA, autoimmune thyroiditis and type 1 diabetes
were comorbid more often than expected, there was re-
duced comorbidity of multiple sclerosis and RA [6].
Our objective was to investigate the prevalence of fa-
milial autoimmunity among subjects with JIA, cSLE
and JDM in the CARRA Registry, the largest multicen-
ter observational Registry for pediatric rheumatic dis-
ease. We sought to explore if there were distinct
patterns of familial clustering of autoimmune diseases
among these phenotypes
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Subjects and methods
Children with JIA, cSLE and JDM from pediatric
rheumatology clinics in the US were enrolled in the
CARRA Registry between May 2010 and May 2012.
Demographic and disease-related data were collected
from time of diagnosis to enrollment visit as previously
described [12–14]. Demographic variables including
gender, race and ethnicity, as well as quality of life mea-
sures were collected by self-report by patients and/or
parents via a questionnaire. Family history information
included the presence of an autoimmune disease in any
first degree relative of the proband. Specifically the fol-
lowing disorders was queried: SLE, psoriasis, Crohn’s
disease or ulcerative colitis, ankylosing spondylitis/spon-
dyloarthropathy, acute anterior uveitis, JIA, RA, multiple
sclerosis, autoimmune thyroiditis, celiac disease, and
type 1 diabetes. In addition, an “other autoimmune dis-
orders” category was included. ANA status, age at onset
of disease, age at diagnosis and age at enrollment were
available by chart review. Institutional Review Board ap-
proval was given for this study by Emory University.
CARRA sites also had local IRB approval to provide data
to the CARRA Registry.
Statistical methods
All statistical analyses were conducting using SAS 9.3
(Cary, NC). Statistical significance was assessed at 0.05
unless otherwise noted. Demographic and disease char-
acteristics are summarized using means and standard
deviations or counts and frequencies for each auto-
immune disorder (subgroup), as appropriate. Demo-
graphic characteristics were compared among the three
groups using one-way analysis of variance (ANOVA)
models for continuous data and Chi-square tests for cat-
egorical data. For each autoimmune disorder (JIA, cSLE,
and JDM), we calculated the proportion of children that
had a first-degree relative with any type of autoimmun-
ity. To determine if subjects with JIA, cSLE, or JDM had
a different proportion of first-degree relatives with auto-
immunity, we performed Chi-square tests or Fisher
Exact tests if the frequencies were small (n < 5). When a
significant difference was detected, post-hoc pairwise
comparisons, adjusted for multiple comparisons, were
made among the three groups to determine which
groups significantly differed using a significance level of
0.05/3 = 0.017. Additionally, Chi-square tests were used
to compare the proportion of children within JIA categor-
ies [15] (systemic, rheumatoid factor (RF)-negative polyar-
ticular JIA, RF-positive polyarticular JIA, persistent
oligoarticular JIA, extended oligoarticular JIA, psoriatic
JIA, ERA, and undifferentiated JIA) that had a first-degree
relative with autoimmunity. While we investigated if over-
all differences in the prevalence of familial autoimmunity
existed between the different categories of JIA, we were
not powered to perform pairwise comparisons between
sets of JIA categories. Finally, the total number of familial
autoimmune diseases was tabulated for each patient. The
Kruskal-Wallis one-way analysis of variance was used to
determine if number of familial autoimmune diseases sig-
nificantly differed by disease group. Additionally, the
number of familial autoimmune diseases was categorized
into the following categories: 0, 1–2, 3 or more and com-
pared among the three disease groups.
Results
Patient characteristics
The sample consisted of 5756 patients with JIA (n =
4677), cSLE (n = 639) or JDM (n = 440) from the
CARRA registry. The majority of the patients were clas-
sified as having JIA (81.3 %), being female (73.3 %) and
Caucasian (85.3 %). The average age of patients in the
dataset at enrollment was 11.9 years (±4.8) and the aver-
age age at onset of symptoms was 7.1 years (±4.7).
Table 1 provides a summary of patient demographics for
the entire sample and broken down by disease group
(JIA, cSLE and JDM). Patients with a diagnosis of JDM
or JIA were younger than patients with a diagnosis of
cSLE (JDM: 11.9 ± 4.4 years; JIA: 11.0 ± 4.4; cSLE: 16.0 ±
3.2 years; p < 0.001) and had a younger-age at onset of
symptoms (p < 0.001). Additionally, cSLE patients were
more likely to be female and African-American or Asian
compared to patients with JIA or JDM. Other differences
were found between groups related to quality of life
measures and ANA positivity.
Family history of autoimmune disease
We compared the proportion of children with first-
degree relatives with various autoimmune diseases
among the three diagnosis groups (Fig. 1 and Table 2).
The proportion of patients having first degree relatives
with any autoimmune disease in the JDM group (20.5 %)
was significantly less compared to patients with JIA
(31.8 %, p < 0.001) and patients with cSLE (31.9 %; p <
0.001). There were no statistically significant differences
in the proportion of JIA, cSLE and JDM patients with
first degree relatives that had autoimmune thyroiditis,
multiple sclerosis, acute anterior uveitis or other auto-
immune disorders.
JIA versus cSLE
Compared to subjects with cSLE, a significantly greater
proportion of patients with JIA had first-degree relatives
with any inflammatory arthritis (p = 0.007), ankylosing
spondylitis (p = 0.016), JIA (p = 0.001), psoriasis (p < 0.001),
Crohn’s disease or ulcerative colitis (p = 0.002), and auto-
immune thyroiditis (p = 0.005). In contrast, compared to
JIA, a significantly higher proportion of patients with cSLE
had first-degree relatives with SLE (p < 0.001) and type-I
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diabetes (p < 0.001). A similar proportion of cases with JIA
and cSLE had FDR with RA (7.3 % vs 7.8 %, p = ns).
JIA versus JDM
Compared to patients with JDM, a significantly greater
proportion of patients with JIA had first-degree relatives
with JIA (p < 0.001), RA (p = 0.002), and any inflamma-
tory arthritis (p < 0.001) (Table 2).
cSLE versus JDM
Compared to patients with JDM, a significantly higher
proportion of patients with cSLE had first-degree
relatives with any inflammatory arthritis (p = 0.003), RA
(p = 0.003), SLE (p < 0.001), and type-1 diabetes (p <
0.001) (Fig. 1 and Table 2).
We also calculated the mean and median number of
familial autoimmune diseases a child had for each diag-
nosis group (Table 3). Overall, there was a difference in
the distribution of the number of familial autoimmune
diseases with JDM having significantly fewer familial dis-
eases compared to JIA (p < 0.001) and cSLE (p < 0.001).
In addition, after classifying the number of familial dis-
eases into 0, 1–2, and 3 or more, we showed that chil-
dren with JIA or cSLE were more likely to have at least
Fig. 1 Familial autoimmunity among subjects with JIA, cSLE and JDM. Proportion of cases with JIA, cSLE and JDM that report having first degree
relatives with various autoimmune disorders. Asterisks denote differences that are statistically significant after correction for multiple testing
Table 1 Comparison demographics groups among disease groups
Characteristic Total JIA SLE JDM p-value
Total number 5,756 4,677 639 440
Female gender N (%) 4,218 (73.3) 3,368 (79.9) 532 (83.4) 318 (72.3) <0.001
Age at enrollment (years) 11.9 ± 4.8 11.4 ± 4.8 16.0 ± 3.2 11.0 ± 4.4 <0.001
Age onset of symptoms (years) 7.1 ± 4.7 6.5 ± 4.5 12.3 ± 3.2 6.6 ± 3.8 <0.001
Race N (%)
AAa 551 (9.6) 269 (5.8) 225 (35.2) 57 (13.0) <0.001
AIb 95 (1.7) 73 (1.6) 12 (1.9) 10 (2.3) 0.476
Asian 197 (3.4) 116 (2.5) 69 (10.8) 12 (2.7) <0.001
NHc 36 (0.6) 25 (0.5) 8 (1.3) 3 (0.7) 0.096
White 4,912 (85.3) 4,244 (90.7) 307 (48.0) 361 (82.1) <0.001
Other 222 (3.9) 146 (3.1) 51 (8.0) 25 (5.7) <0.001
Ethnicity (Non-Hispanic) N (%) 5,059 (87.9) 4,214 (90.1) 464 (72.6) 381 (86.6) <0.001
Overall Well-being Score 2.3 ± 2.3 2.3 ± 2.3 2.6 ± 2.5 2.1 ± 2.3 <0.001
PGA 1.6 ± 1.9 1.6 ± 1.9 2.0 ± 1.9 1.6 ± 1.9 <0.001
CHAQ 0.34 ± 0.51 0.35 ± 0.51 0.24 ± 0.46 0.36 ± 0.63 <0.001
ANA N (% positive)d 2,802 (56.2) 2,012 (49.7) 577 (96.5) 213 (62.3) <0.001
aAA – African American or Black, bAI- American Indian or Alaskan Native
cNH- Native Hawaiian or Pacific Islander, dIndicates missing data
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1 familial autoimmune disease reported compared to
children with JDM (p < 0.001).
Family history of autoimmunity among subjects with JIA
categories
We then compared the proportion of familial auto-
immunity among first-degree relatives of children with
the different JIA categories (Table 4). Overall, there were
significant differences in the proportion of any familial
autoimmunity among the JIA categories (p < 0.001).
Additionally, among the categories, there was a signifi-
cant difference in the proportion of children with first-
degree relatives with a history of psoriasis (p < 0.001),
ankylosing spondylitis (p < 0.001), spondyloarthropathy
(p < 0.001), Crohn’s disease or ulcerative colitis (p =
0.001), acute anterior uveitis (p = 0.005), JIA (p = 0.047),
RA (p < 0.001), and any inflammatory arthritis (p <
0.001).
Discussion
Autoimmune disorders are common, estimated to affect
5-10 % of the population. Clinical and genetic studies
support the hypothesis that clinically distinct auto-
immune disorders share common genetic susceptibility
factors [1, 16, 17]. Familial aggregation of SLE, RA and
other autoimmune diseases have been reported in pro-
bands with SLE [18]. Previously studies of small cohorts
have shown familial aggregation of autoimmunity in JIA,
JDM and cSLE [9–11]. In a study of 69 subjects with
cSLE, 32 % of subjects had one or more first degree
Table 2 Comparison of cases with JIA, cSLE and JDM with autoimmune disorders among first-degree relatives
Family history of disease Disease group P-
valueJIA cSLE JDM
(N = 4,677) (N = 639) (N = 440)
Any autoimmune disease 1,488 (31.8) 204 (31.9) 90 (20.5)a b <0.001
Inflammatory Arthritis -(AS, Spondyloarthropathy, JIA, RA) 608 (13.0) 59 (9.2)a 19 (4.3)a b <0.001
Ankylosing spondylitis 61 (1.3) 1 (0.2)a 2 (0.5) 0.014
Spondyloarthropathy 36 (0.8) 0 (0.0) 0 (0.0) 0.015
JIA 241 (5.2) 14 (2.2)a 4 (0.9)a <0.001
RA 340 (7.3) 50 (7.8) 15 (3.4)a b 0.007
Crohn’s disease or ulcerative colitis 126 (2.7) 4 (0.6)a 5 (1.1) 0.002
Acute anterior uveitis 15 (0.3) 0 (0.0) 0 (0.0) 0.169
Psoriasis 372 (8.0) 16 (2.5)a 22 (5.0) <0.001
SLE 77 (1.7) 71 (11.1)a 5 (1.1)b <0.001
Multiple Sclerosis 45 (1.0) 7 (1.1) 5 (1.1) 0.905
Autoimmune thyroiditis 248 (5.3) 17 (2.7)a 24 (5.5) 0.015
Celiac 36 (0.8) 5 (0.8) 6 (1.4) 0.439
Type 1 Diabetes 147 (3.1) 47 (7.4)a 13 (3.0)b <0.001
Other autoimmune 214 (4.6) 32 (5.0) 20 (4.6) 0.893
All values are N (%)
aSignificantly different from JIA (p < 0.017)
bSignificantly different from SLE (p < 0.017)
Table 3 Comparison of the number of autoimmune disease (family history) among disease groups
Outcome Level Disease group P-value
JIA SLE JDM
(N = 4,677) (N = 639) (N = 440)
# of autoimmune diseases in family
Mean ± SD – 0.4 ± 0.8 0.4 ± 0.7 0.3 ± 0.6 <0.001
Median 0 0 0
(Range) (0 – 14) (0 – 5) (0 – 4)
# of autoimmune diseases in family 0 3189 (66.2 %) 435 (68.1 %) 350 (80.8 %) <0.001
1-2 1377 (29.4 %) 192 (30.1 %) 82 (18.6 %)
3+ 111 (2.4 %) 12 (1.9 %) 8 (1.8 %)
Prahalad et al. Pediatric Rheumatology  (2016) 14:14 Page 4 of 7
relatives with autoimmune diseases which matches find-
ings from our study [10]. However, there have not been
systematic investigations of large cohorts of children
with JIA, SLE and JDM to determine if there are specific
patterns of familial clustering with these phenotypes.
Our results suggest that the prevalence of autoimmun-
ity is increased among first degree relatives of subjects
with JIA and cSLE compared to those of JDM. Relatives
of subjects with cSLE had an increased prevalence of
SLE, and relatives of subjects with JIA were enriched for
inflammatory arthropathies. Relatives of children with
cSLE also had a higher prevalence of type-1 diabetes
compared to relatives of cases with JIA or JDM. These
results highlight the complex nature of familial auto-
immunity suggesting that while prevalence of clinically
distinct autoimmune phenotypes are increased among
family members of cases with JIA, cSLE and JDM, there
are distinct patterns of familial clustering of diseases
among these phenotypes.
Our results suggest that familial autoimmunity is
lower in JDM compared to JIA or cSLE. Since the sam-
ple sizes of our JDM and cSLE cohorts were of similar
magnitude, we believe that this is a true difference and
not influenced by the potential number of relatives. One
possible reason for this observation could be due to a
potentially greater contribution of environmental factors
to JDM compared to JIA or cSLE. While genome wide
association studies of JIA [19] and SLE [20, 21] have
resulted in the discovery of a number of associated loci
both within and outside the MHC region, in inflamma-
tory myopathies, only HLA variants are associated at
genome wide levels of significance, although the sample
sizes for inflammatory myopathies was modest at 1700
cases [22]. It is also possible that susceptibility genes that
underlie JDM might be different compared to JIA and/
or cSLE. Emerging studies of multiple autoimmune phe-
notypes using shared controls might allow for a better
understanding of shared genetic associations between
clinically distinct phenotypes, which in turn might have
implications towards understanding their pathophysi-
ology and therapy [23]. Future investigations of subjects
in families with multiple autoimmune disorders to
characterize shared genomic, transcriptomic and prote-
omic factors would further enhance our understanding
of the complex relationship between different auto-
immune phenotypes.
When we compared the different JIA categories, we
found that systemic JIA cases had lower proportion of
first degree relatives with any autoimmune disease
(21.7 %) compared to other JIA categories, which is con-
sistent with the idea that systemic JIA may be phenotyp-
ically and genetically distinct from other JIA categories
[24]. Since family history of psoriasis and spondyloar-
thropathy is part of the criteria for classifying patients
into psoriatic JIA and ERA respectively, this could have
biased the observed higher prevalence of autoimmunity
Table 4 Comparison of cases with different JIA categories with autoimmune disorders among first-degree relatives
Family history of disease JIA categorya P-valueb
(N = 4441)
Systemic Poly RF(−) Poly RF(+) Oligo persistent Oligo extended Psoriatic ERA Undiff
(N = 355) (N = 1313) (N = 294) (N = 1293) (N = 340) (N = 273) (N = 451) (N = 122)
Any autoimmune disease 77 (21.7) 408 (31.1) 87 (29.6) 344 (26.6) 97 (28.5) 146 (53.5) 186 (41.2) 54 (44.3) <0.001
Inflammatory arthritisc 26 (7.3) 169 (12.9) 36 (12.4) 137 (10.6) 36 (10.6) 5 2 (19.1) 97 (21.5) 24 (19.7) <0.001
Ankylosing spondylitis 0 (0.0) 4 (0.3) 1 (0.3) 7 (0.5) 0 (0.0) 2 (0.7) 37 (8.2) 5 (4.1) <0.001
Spondyloarthropathy 1 (0.3) 2 (0.2) 1 (0.3) 3 (0.2) 0 (0.0) 5 (1.8) 17 (3.8) 2 (1.6) <0.001
JIA 10 (2.8) 83 (6.3) 10 (3.4) 67 (5.2) 13 (3.8) 13 (4.8) 32 (7.1) 5 (4.1) 0.047
RA 17 (4.8) 95 (7.2) 25 (8.5) 76 (5.9) 24 (7.1) 37 (13.6) 32 (7.1) 16 (13.1) <0.001
Crohn’s disease or ulcerative colitis 4 (1.1) 35 (2.7) 7 (2.4) 27 (2.1) 6 (1.8) 6 (2.2) 26 (5.8) 6 (4.9) 0.001
Acute anterior uveitis 0 (0.0) 7 (0.5) 0 (0.0) 1 (0.1) 1 (0.3) 0 (0.0) 6 (1.3) 0 (0.0) 0.005
Psoriasis 20 (5.6) 78 (5.9) 11 (3.7) 70 (5.4) 17 (5.0) 96 (35.2) 31 (6.9) 20 (16.4) <0.001
SLE 7 (2.0) 26 (2.0) 5 (1.7) 17 (1.3) 5 (1.5) 2 (0.7) 7 (1.6) 5 (4.1) 0.338
Multiple Sclerosis 3 (0.9) 14 (1.1) 2 (0.7) 10 (0.8) 6 (1.8) 3 (1.1) 2 (0.4) 3 (2.5) 0.410
Autoimmune thyroiditis 16 (4.5) 74 (5.6) 17 (5.8) 62 (4.8) 22 (6.5) 23 (8.4) 17 (3.8) 6 (4.9) 0.198
Celiac 1 (0.3) 7 (0.5) 0 (0.0) 15 (1.2) 2 (0.6) 0 (0.0) 6 (1.3) 1 (0.8) 0.113
Type 1 Diabetes 12 (3.4) 41 (3.1) 14 (4.8) 32 (2.5) 8 (2.4) 11 (4.0) 14 (3.1) 6 (4.9) 0.406
Other autoimmune 12 (3.3) 68 (5.1) 10 (3.3) 50 (3.8) 12 (3.5) 14 (5.1) 25 (5.4) 6 (4.7) 0.504
achildren with missing JIA category information were excluded. All values are N (%)
bSignificance values for overall differences between JIA categories
cInflammatory arthritis includes AS, spondyloarthropathy, JIA and RA
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among relatives of psoriatic JIA and ERA cases. Interest-
ingly the prevalence of SLE, autoimmune thyroiditis,
MS, celiac disease and type 1 diabetes did not differ sig-
nificantly between relatives of different JIA categories.
Our study had several strengths. The data for the
CARRA Registry was collected from a majority of pediatric
rheumatology centers in the USA, which means our results
apply to a broad population of childhood rheumatic dis-
eases. In addition to being the first to compare familial
autoimmunity among JIA, cSLE and JDM, our study com-
prised of large cohorts with JIA, cSLE and JDM. Our JIA
cohort was also sufficiently large which allowed us to in-
vestigate differences between different JIA categories.
Our study has potential limitations as well. The
CARRA Registry did not collect family history of idio-
pathic inflammatory myopathy specifically. This could
have resulted in an underrepresentation of inflammatory
myopathy in these families. However, two smaller studies
of probands with idiopathic inflammatory myopathies
did not find an increased prevalence of first degree rela-
tives with inflammatory myopathy [9, 25]. Furthermore,
an “other” category was included which might have ex-
pected to capture information if subjects with JDM had
increased numbers of relatives with inflammatory myop-
athies. The CARRA Registry also did not collect individ-
ual data on which relative had the autoimmune disorder
or the number of first-degree relatives to provide a de-
nominator. We do not believe that this limitation affects
our conclusion that compared to first degree relatives of
JDM cases, there is increased autoimmunity among first
degree relatives of patients with JIA and cSLE. Since
families of probands with JIA, cSLE and JDM completed
the same baseline demographic forms it is unlikely that
there was bias in reporting of first degree relatives with
autoimmune disorders between JIA, cSLE and JDM. The
lack of data to discriminate autoimmunity status of indi-
vidual relatives limits us from estimating the prevalence
of autoimmunity among relatives or potential parent of
origin effects, but we do not believe there to be inherent
differences in number of relatives among JIA, cSLE or
JDM families. Finally, our subjects are from North
America, and majority (85 %) were Caucasian, which
might limit the generalizability of the study to other re-
gions and ethnicities.
Conclusion
In conclusion, we have shown JIA and cSLE cases more
often have first-degree relatives with autoimmunity com-
pared to JDM cases. The demonstration that a greater
proportion of JIA cases have first-degree relatives with
inflammatory arthritis, and a greater proportion of cSLE
cases have first-degree relatives with SLE suggests that
there are distinct patterns of familial autoimmunity. Fu-
ture studies, including investigation of genomic and
proteomic biomarkers among subjects with different
autoimmune phenotypes as well as their relatives would
substantially improve our understanding of the complex
interplay between different autoimmune phenotypes.
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